octreotide (Sandostatin, Sandostatin LAR)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.




  • Octreotide injection is available in ampuls and vials.
  • Ampuls containing solution for injection: 0.05, 0.1, 0.2, 0.5, and 1 mg/ml
  • Depot injection (Sandostatin LAR): 10, 20, and 30 mg per vial


  • Octreotide acetate is stored in the refrigerator between 36 F and 46 F (2 C to 8 C).
  • It should be stored in its outer carton to protect it from light.
  • If stored at room temperature, octreotide acetate is stable for 14 days if protected from light.
  • Prior to injection the solution should be allowed to warm up to room temperature.
  • The manufacturer recommends against the use of artificial means to warm up the solution.
  • Multi-dose vials should be used within 14 days of opening.
  • Ampuls are intended for single-use only and any unused portion should be discarded after opening.


  • Although injection into fatty tissue (subcutaneously) is preferred, octreotide acetate also can be given by injection into the vein (intravenously). Hands should be washed before and after administration.
  • Before injecting, octreotide should be allowed to come to room temperature.
  • To decrease pain associated with subcutaneous injection the smallest possible volume to deliver the drug should be used.
  • Injection sites should be rotated to decrease injection site reactions.
  • If the solution becomes cloudy, has particles, or is leaking, it should not be used. Used needles should be thrown away in a needle or sharps container.

Acromegaly treatment

  • Treatment may be started with 50 mcg three times daily. For most patients, 100 mcg three times daily was found to be effective. However, some patients required up to 500 mcg three times daily.

Carcinoid tumor treatment

  • To treat symptoms of severe diarrhea and flushing in patients with metastatic carcinoid tumors, the recommended daily dose of octreotide acetate during the first 2 weeks of treatment ranges from 100-600 mcg/day in 2-4 divided doses (average daily dose is 300 mcg).

Vasoactive intestinal peptide tumor (VIPomas) treatment

  • To treat severe diarrhea associated with VIP-secreting tumors, the recommended daily dose of octreotide acetate during the first 2 weeks of therapy is 200-300 mcg in 2-4 divided doses (150-700 mcg) to achieve symptom control. Dose may be adjusted based on individual patient response but usually doses > 450 mcg/day are not required.
Medically Reviewed by a Doctor on 6/2/2015

Quick GuideDigestive Disorders: Common Misconceptions

Digestive Disorders: Common Misconceptions
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors